PMID- 31568056
OWN - NLM
STAT- MEDLINE
DCOM- 20201207
LR  - 20210208
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 38
IP  - 1
DP  - 2020 Jan
TI  - Apparent therapy-resistant hypertension as risk factor for the development of 
      type 2 diabetes mellitus.
PG  - 45-51
LID - 10.1097/HJH.0000000000002227 [doi]
AB  - OBJECTIVE: To evaluate whether the relationship between hypertension and type 2 
      diabetes mellitus (T2DM) is different for patients with uncontrolled 
      hypertension, controlled hypertension or patients with apparent therapy-resistant 
      hypertension (aTRH), compared with patients without hypertension. METHODS: Using 
      Cox proportional hazard models we evaluated the risk of new-onset T2DM in 8756 
      patients, at high risk for vascular disease. Hypertensive patients were 
      subdivided according to blood pressure (BP) and use of BP-lowering drugs. BP >/= 
      140/90 mmHg was defined as uncontrolled BP. aTRH was defined as uncontrolled BP 
      despite being treated with at least three BP-lowering drugs including a diuretic, 
      or the use at least four BP-lowering drugs irrespective of BP levels. Further 
      analysis evaluated the risk of new-onset T2DM for patients with uncontrolled 
      hypertension and for patients with aTRH, compared with patients with controlled 
      hypertension and without hypertension, respectively. RESULTS: Forty-five percent 
      had controlled hypertension, 20% had uncontrolled hypertension, 5.7% had aTRH, 
      and 29% were nonhypertensive. During a follow-up of 7.0 (interquartile range: 
      0-14) years there were 705 new cases of T2DM. Patients with hypertension had a 
      1.48 (95% confidence interval 1.22-1.80) times higher risk of new-onset T2DM than 
      nonhypertensive patients. There was no significant difference in risk among 
      different hypertension groups. CONCLUSION: Patients at high risk for 
      cardiovascular disease with hypertension have a 1.48 times higher risk of 
      new-onset T2DM than nonhypertensive counterparts. The risk did not differ between 
      patients with controlled hypertension, uncontrolled hypertension, or aTRH.
FAU - Holtrop, Joris
AU  - Holtrop J
AD  - Department of Vascular Medicine Department of Cardiology Department of Vascular 
      Surgery Department of Neurology and Neurosurgery Department of Diabetology, 
      University Medical Centre Utrecht, Utrecht, The Netherlands.
FAU - Spiering, Wilko
AU  - Spiering W
FAU - Nathoe, Hendrik M
AU  - Nathoe HM
FAU - De Borst, Gert J
AU  - De Borst GJ
FAU - Kappelle, Laurens J
AU  - Kappelle LJ
FAU - De Valk, Harold W
AU  - De Valk HW
FAU - Visseren, Frank L J
AU  - Visseren FLJ
FAU - Westerink, Jan
AU  - Westerink J
CN  - SMART Study Group
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Antihypertensive Agents/*therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Humans
MH  - *Hypertension/complications/drug therapy/epidemiology
MH  - Risk Factors
MH  - Treatment Failure
EDAT- 2019/10/01 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/10/01 06:00
PHST- 2019/10/01 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/10/01 06:00 [entrez]
AID - 00004872-202001000-00009 [pii]
AID - 10.1097/HJH.0000000000002227 [doi]
PST - ppublish
SO  - J Hypertens. 2020 Jan;38(1):45-51. doi: 10.1097/HJH.0000000000002227.